Keeley Teton Advisors LLC Has $1.36 Million Stake in Orthofix Medical Inc. $OFIX

Key Points

• Keeley Teton Advisors LLC increased its position in Orthofix Medical Inc. by 36.4% during the first quarter, owning 83,657 shares worth approximately $1.36 million.
• Orthofix Medical has an average rating of Buy from analysts, with a target price of $21.50, following upgrades from several brokerages.
• Despite a quarterly revenue of $203.12 million, Orthofix Medical reported a loss of ($0.36) earnings per share, missing the consensus estimate significantly.

Keeley Teton Advisors LLC grew its position in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 36.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 83,657 shares of the medical device company's stock after acquiring an additional 22,320 shares during the quarter. Keeley Teton Advisors LLC owned about 0.21% of Orthofix Medical worth $1,364,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of OFIX. Juniper Investment Company LLC grew its stake in shares of Orthofix Medical by 123.5% in the fourth quarter. Juniper Investment Company LLC now owns 1,937,249 shares of the medical device company's stock valued at $33,824,000 after buying an additional 1,070,656 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Orthofix Medical by 31.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 659,475 shares of the medical device company's stock valued at $11,515,000 after buying an additional 159,177 shares in the last quarter. Emerald Mutual Fund Advisers Trust grew its stake in shares of Orthofix Medical by 35.4% in the fourth quarter. Emerald Mutual Fund Advisers Trust now owns 503,802 shares of the medical device company's stock valued at $8,796,000 after buying an additional 131,653 shares in the last quarter. Boone Capital Management LLC grew its stake in shares of Orthofix Medical by 13.6% in the fourth quarter. Boone Capital Management LLC now owns 1,057,313 shares of the medical device company's stock valued at $18,461,000 after buying an additional 126,806 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in Orthofix Medical during the 1st quarter valued at approximately $1,445,000. Institutional investors and hedge funds own 89.76% of the company's stock.

Orthofix Medical Stock Performance

Orthofix Medical stock traded up $0.24 during mid-day trading on Monday, hitting $14.98. 534,055 shares of the company's stock traded hands, compared to its average volume of 536,330. Orthofix Medical Inc. has a one year low of $10.24 and a one year high of $20.73. The company has a market cap of $591.62 million, a PE ratio of -4.73 and a beta of 0.86. The firm has a 50 day moving average price of $12.16 and a 200 day moving average price of $13.44. The company has a quick ratio of 1.50, a current ratio of 2.67 and a debt-to-equity ratio of 0.38.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.40). The firm had revenue of $203.12 million for the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. Orthofix Medical has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Orthofix Medical Inc. will post -2.81 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on OFIX shares. JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a research note on Friday, June 6th. Barrington Research raised Orthofix Medical to a "strong-buy" rating and set a $16.00 target price on the stock in a report on Monday, June 23rd. Finally, Wall Street Zen raised Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Orthofix Medical currently has an average rating of "Buy" and an average target price of $21.50.

Insider Activity at Orthofix Medical

In other news, insider Aviva Mcpherron sold 3,728 shares of the firm's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total transaction of $39,181.28. Following the completion of the sale, the insider directly owned 46,322 shares of the company's stock, valued at $486,844.22. This trade represents a 7.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.30% of the company's stock.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.